AMN082

AMN082 acts at an allosteric site on the mGlu7 receptor rather than the orthosteric glutamate pocket, allowing selective activation of a receptor that is otherwise difficult to engage because it requires unusually high glutamate concentrations. As a group III receptor, mGlu7 is a presynaptic autoreceptor and heteroreceptor that inhibits neurotransmitter release, and it is implicated in the regulation of stress, fear and reward circuits. In behavioural studies AMN082 modulated fear learning and memory and reduced anxiety-like behaviour associated with ethanol and morphine withdrawal, effects that were reversed by the mGlu7 antagonist MMPIP, supporting an mGlu7-mediated action ^[1]. It also produced dose-dependent antidepressant-like effects in the forced swim and tail suspension tests that were absent in mGlu7 knockout mice, providing genetic confirmation that the behavioural activity is mGlu7-dependent even though high doses cause off-target hypolocomotion ^[3].

AMN082 has also served as the anchor tool in medicinal-chemistry efforts to find better mGlu7 ligands. Computational and screening campaigns explicitly benchmarked new allosteric agonists against AMN082, seeking analogues with comparable potency but more favourable drug-like properties, since AMN082 is known to undergo rapid metabolism to a byproduct with monoamine transporter activity that can confound in vivo results ^[2]. Despite these caveats, the compound remains historically pivotal for establishing that mGlu7 is a druggable and behaviourally relevant target in anxiety, depression and substance-withdrawal states ^[1][2]. It is used strictly as a research probe rather than a therapeutic.

As a research reagent, AMN082 has no human safety characterization and is used only in laboratory studies. Its known metabolic conversion to a monoamine-transporter-active byproduct is an important experimental caveat rather than a clinical safety finding, and it means some reported effects may not be purely mGlu7-mediated. It is investigational and not intended for human use.

AMN082 was reported in the mid-2000s as the first selective allosteric agonist of mGlu7, immediately filling a gap because no good tool existed to activate this receptor pharmacologically. It became widely adopted for probing mGlu7 in stress and addiction and later served as the reference structure for computationally guided discovery of improved mGlu7 agonists. The receptor itself gained attention through genetic studies linking mGlu7 to anxiety and cognitive phenotypes.

AMN082 is well known among metabotropic glutamate researchers as the pioneering mGlu7 agonist, and it is frequently cited both for its usefulness and for its off-target pitfalls. It is regarded as a proof-of-concept tool that made mGlu7 experimentally accessible rather than a therapeutic lead. Its reputation is that of an indispensable but imperfect probe.